drugset / Trial / NCT00007774

To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia

NCT00007774

Double-blind

Summary

Although currently marketed antipsychotic drugs are useful in the treatment of schizophrenia, efficacy and safety profiles need to be improved. Forty to eighty percent of patients either fail to respond or only partially respond to conventional antipsychotic agents. Secondary symptoms may be unimproved even in patients who respond to treatment. A variety of adverse events occur in patients receiving currently available agents. The severity of these events contributes to the poor compliance that is observed in this patient population. Olanzapine is a novel antipsychotic agent with a reduced incidence of extrapyramidal symptoms. Other side effects are minimal.

Timeline

Start
1998-03
Primary completion
2001-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Haloperidol Other / unclassified 5 mg
Comparator Haloperidol Other / unclassified 20 mg
Subject Olanzapine Small molecule 5 mg Oral
Subject Olanzapine Small molecule 20 mg Oral